CTLA4 and neoplasm: In murine models of small-cell lung cancer, melanoma, and TNBC, BET inhibitor enhances tumor antigen presentation, increases cytotoxic T cell infiltration, and synergizes with PD-1/PD-L1 or CTLA-4 checkpoint blockade (185).